Key Proteo, Inc.
About Key Proteo, Inc.
Key Proteo, Inc. is a Seattle-based medtech company founded in 2019 focused on rapid proteomic screening technology for detecting rare genetic disorders in newborns. Its mission is to enable early intervention for treatable genetic disorders through a dynamic proteomics-based platform that can be adapted across patient populations. The company’s patent-pending Immuno-SRM platform and associated reagent kits support newborn screening for conditions such as Wilson Disease, Wiskott-Aldrich Syndrome, XLA, and ADA. It recently submitted a De Novo application to the FDA for its first newborn screening kit.
- 🔗 Key Proteo, Inc. — $3M raised | Noair Lab
- 🔗 Key Proteo Submits De Novo Application to FDA for its First Newborn Screening Kit
- 🔗 Key Proteo Submits De Novo Application to FDA for its First ...
- 🔗 Proteo - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Proteo - 2026 Company Profile, Funding & Competitors - Tracxn
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $3M total via private placement with latest Form D filed May 2023.
- Submitted De Novo FDA application for first newborn screening kit targeting rare genetic disorders.
- Platform uses Immuno-SRM proteomics technology adaptable beyond newborns.
- No federal grants or SBIR/STTR awards recorded.
- Headquartered in Seattle with focus on early detection of treatable disorders like Wilson Disease.
Ask StreetZero about Key Proteo, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account